| Website | ovascience.com |
| Blog | facebook.com/OvaS... |
| @OvaScience | |
| Category | BioTech |
| Phone | 617-902-0682 |
| info@ovascience.com | |
| Employees | |
| Description | A Privately-held Fertility Company |
| TOTAL | $47M |
| VENTURE FUNDING TOTAL | $47M |
| Series A, 10/11 | $6M |
| Series B, 4/12 General Catalyst Partners Bbt Capital Management Cycad Group Hunt BioVentures RA Capital Management | $37M |
| Venture Round, 8/12 | $4M |
The company is applying innovative science to improve the quality of eggs (oocytes) and increase the success of in vitro fertilization (IVF). OvaScience’s proprietary technology, exclusively licensed from Harvard Medical School and Massachusetts General Hospital, enables the use of a women’s own cellular energy to improve egg quality. OvaScience was co-founded by Richard Aldrich, Michelle Dipp, M.D., Ph.D., and Christoph Westphal M.D., Ph.D., of Longwood Founders Fund, along with fertility expert and Harvard Medical School Professor Jonathan Tilly, Ph.D. of Massachusetts General Hospital, and aging expert and Harvard Medical School Professor David Sinclair, Ph.D. The company is backed by leading life science investors Longwood Founders Fund and Bessemer Venture Partners. The company has assembled a world-class team of leading reproductive endocrinologists, embryologists, scientists and advisers to bring this technology to patients.
